Strategies for Preventing Endoscopic Recurrence of Crohn’s Disease 1 Year after Surgery: A Network Meta-Analysis

Table 1

Result of network meta-analysis.

	Mean	SD	MC_error	val2.5pc	Median	val97.5pc	Intervention
d[2]	−0.8045	2.202	0.0506	−4.705	−1.068	4.443	MSLZ 4 g/d
d[3]	−1.053	1.715	0.03574	−4.16	−1.201	3.03	MSLZ 2-3/d
d[4]	−1.389	2.222	0.0498	−5.236	−1.628	3.899	AZA
d[5]	−0.4136	1.244	0.007319	−3.051	−0.406	2.152	BDND
d[6]	−5.475	2.222	0.04268	−10.47	−5.287	−1.632	IFX (0/2/6/E8W)
d[7]	−7.273	2.849	0.06321	−13.84	−6.948	−2.585	ADA 160/80/40
d[8]	−0.05878	2.438	0.03836	−4.637	−0.2134	5.522	Untreated
d[9]	−1.174	2.47	0.05239	−5.73	−1.367	4.581	TW
d[10]	1.062	1.848	0.01396	−2.81	1.075	4.86	LGG
d[11]	−3.795	2.943	0.05731	−9.191	−4.021	3.016	MSLZ (2-3 g) + IFX (5 mg/kg, E8W)
d[12]	−1.818	1.757	0.01178	−5.519	−1.814	1.87	ONDZ

Untreated, blank control group; MSLZ: mesalazine; BDND: budesonide; AZA: azathioprine; IFX: infliximab; ADA: adalimumab; TW: Tripterygium wilfordii; LGG: Lactobacillus GG; d[2] indicates the log odds ratio between treatment 2 and treatment 1 (d[1]); d[3] indicates the log odds ratio between treatment 3 and treatment 1 and so on.